Tekla Life Sciences Investors
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel R. Omstead
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 100 Federal Street Philadelphia PA United States of America 02110
- IPO Date
- May 1, 1992
- CIK
- 0000884121
- Website
- abrdnhql.com
- Similar Companies
- Business
- Tekla Life Sciences Investors Tekla Life Sciences Investors is a non-diversified closed-end management investment company that seeks long-term capital appreciation primarily through investments in securities of life sciences companies, including public and private equities focused on biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies, agriculture, and environmental management industries; it primarily targets growth stocks of small-cap companies worldwide, with up to 20% of net assets in foreign issuers mainly from Western Europe, Canada, and Japan, employing fundamental analysis based on market position, management experience, technological expertise, and capital access. The fund, managed by abrdn Inc., benchmarks performance against the NASDAQ Biotech Index and S&P 500 Index. Headquartered at 1900 Market Street, Suite 200, Philadelphia, PA 19103, it was formed on February 20, 1992, formerly as H&Q Life Sciences Investors, and operates globally with a focus on U.S. markets. In recent developments, Tekla Capital Management LLC, its prior adviser, completed the sale of its advisory business to abrdn Inc. in October 2023, resulting in abrdn's approval as investment manager; the fund renewed its share repurchase program in 2023 and 2024, authorizing purchases of up to 12% of outstanding shares to enhance shareholder value and narrow the market price-to-NAV discount; it also initiated new portfolio positions in 2025, including Janux Therapeutics, Inc., CARGO Therapeutics, Inc., EyePoint Pharmaceuticals, Inc., and Inozyme Pharma, Inc., alongside holdings in major names like Gilead Sciences, Inc., Amgen Inc., Regeneron Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, and AstraZeneca PLC.
HQL: Attractive Outlook With Growth Of GLP-1 Market
Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
How To Invest $100,000 Today: 5 Strategies For Success
Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
10 Best CEFs This Month: Average Yield Of 10% (March 2026)
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
How We're Playing ‘AI 2.0' For Big Dividend Payouts
HQL: Dividend Can Be Sustained Through 2026
Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
abrdn Life Sciences Investors (NYSE:HQL) Short Interest Down 34.6% in December
ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS
HQL: Still Offers Attractive Value As Long As Interest Rates Decline
ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS
HQL: We Should Be Accumulating During The Weakness
CEF Insights: The Future Of Healthcare Investing
HQL: Positive Outlook Due To Increased Healthcare Spending
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
5 Best CEFs This Month For Yields Up To 14%
HQL: Attractive Valuation, Aligned To Benefit From Aging Gen X